Provectus Biopharmaceuticals expands its research collaboration

KNOXVILLE, TN, Oct. 25, 2022 (GLOBE NEWSWIRE) — Provectus (OTCQB: PVCT) today announced that the company has expanded its sponsored research program with James G. Krueger, MD, PhD, co-director, Center for Clinical and Translational Science, D. Martin Carter Professor of Clinical Research, Senior Attending Physician and Head of the Laboratory of Investigative Dermatology at Rockefeller University to study the potential of PH-10, a topical formulation of the small molecule rose Provectus Sodium Pharmaceutical Grade Bengal (RBS), to directly alter the growth and differentiation of human keratinocytes and to block cytokine-mediated signaling that creates different inflammatory skin diseases and may also be important in cutaneous neoplasms.

PH-10 is a clinical-stage, multi-indication viable immuno-dermatological pharmaceutical active that the Company has used to treat more than 200 patients in multiple early and mid-stage clinical trials for psoriasis and atopic dermatitis.

Dr. Krueger and the Experimental Dermatology Laboratory plan to examine the effects of a wider range of PH-10 concentrations on human keratinocytes in vitro at the level of gene transcription. They also hope to determine the interaction and uptake of PH-10 with blood leukocytes, as these cells are involved in inflammatory skin diseases and control or protect against certain types of skin cancers.

The Kruger team previously elucidated several mechanisms of action of PH-10 from work they performed in a Provectus clinical study in psoriasis, showing that:

  • PH-10 treatment significantly down-regulated IL-17A, IL-22, IL-26, IL-36 and keratin 16 genes,
  • Pathways significantly improved by PH-10 treatment included published transcriptomes of psoriasis and cellular responses mediated by IL-17, IL-22 and interferons,
  • PH-10 treatment downregulated more than 500 disease-related genes, and
  • Expression of a wide range of core “psoriasis-related” genes, including IL-23, IL-17, IL-22, S100A7, IL-19, IL-36, and CXCL1, were effectively normalized to consistent levels with undamaged skin.

A copy of the medical conference poster of this earlier work by the Kruger team is available on the Provectus website.

About Provectus

Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company that develops immunotherapy drugs for different disease areas based on a class of small molecules called halogenated xanthenes (HX). The Company’s flagship molecule is sodium rose bengal. A second HX molecule was synthesized.

Provectus’ drug discovery and development programs include investigational drugs and drug targets in oncology (clinical stage), dermatology (clinical stage), hematology, infectious diseases, ophthalmology (clinical stage), animal health and in tissue regeneration and repair, and use multiple routes of administration, such as intralesional (IL), topical (.top), oral (PO), inhaled (.inh), intranasal (IN), and intravenous (IV).

Information about the Company’s clinical trials is available on the National Institutes of Health (NIH) registry, For more information about Provectus, please visit the company’s website at

FORWARD-LOOKING STATEMENTS: Information in this press release may include “forward-looking statements”, within the meaning of United States securities laws, relating to the business of Provectus and its affiliates, which are based on the opinions and estimates of the management of the Company and are subject to various risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “budget”, “plan”, “continue”, “estimate”, “expect”, “plan”, “may”, “will”, “project”, “predict”, “potential”, “target”, “intend”, “could”, “could”, “should”, “believe” and similar words suggesting the future of results or statements about a prospect.

The safety and effectiveness of the agents and/or uses under investigation have not been established. There is no guarantee that agents will receive health authority approval or be commercially available in a country for the uses investigated or that these agents as products will achieve particular revenue levels.

Due to the risks, uncertainties and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result new information, future events or otherwise, except in accordance with applicable securities laws. Forward-looking statements are expressly qualified by this cautionary statement.

The risks, uncertainties and assumptions include those discussed in the documents filed by the Company with the Security and Exchange Commission (SECOND)including those described in Section 1A of:



Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Financial director
Phone: (866) 594-5999